Biotechnology News

September 29, 2014

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant,...

September 29, 2014

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Vantage Health Announces Appointment of Edward Rollins, Former Advisor to Four U.S. Presidents, to Its Board of Directors

September 29, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis to present at the International Congress of the World Muscle Society.

September 29, 2014

SAN FRANCISCO--(BUSINESS WIRE)--Today, Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced the planned...

September 29, 2014

YOKOHAMA, Japan--(BUSINESS WIRE)--ReproCELL Launches Cell Innovation Partners, L.P. with Shinsei Bank, Limited

September 29, 2014

PRINCETON, N.J.--(BUSINESS WIRE)--European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer

September 29, 2014

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. doing business as Sevion Therapeutics ("Sevion" or the "Company") (OTCQB:SNTI) today reported financial results for the fiscal year ended June 30, 2014 (“Fiscal 2014”), and also...

September 29, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--ImmuneXcite, Inc., a biopharmaceutical company focused on developing a next generation immunotherapy platform to generate new targeted immunotherapies for cancer employing a unique neutrophils-initiated immune...

September 29, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Daniel R Marshak, PhD to its Board of Directors. Dr. Marshak most recently served as Senior Vice President and Chief Scientific...

September 29, 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals will present at the 2014 Leerink Rare Disease Roundtable, Bernstein’s Genes as Drugs Event, and the 13th Annual BIO Investor Forum.

September 29, 2014

CAMBRIDGE, Mass. & MADRID--(BUSINESS WIRE)--Tokai Pharmaceuticals Presents Updated Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer at ESMO 2014

September 29, 2014

IRVINE, Calif.--(BUSINESS WIRE)--The Board of Directors of Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued the following statement: There has recently been significant and potentially distracting market speculation regarding...

September 29, 2014

SAN RAFAEL, Calif.--(BUSINESS WIRE)--BioCision Opens Global Headquarters in San Rafael, California

September 29, 2014

MADRID & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung...

September 29, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN) will present a corporate overview at the Leerink Partners Rare Disease Roundtable on October 1, 2014 in NYC.

September 29, 2014

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Illinois’ Christopher Rural Health Planning Corporation, a Federally Qualified Health Center (FQHC), has selected eClinicalWorks comprehensive electronic health records (EHR) across its 13 locations.

September 29, 2014

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction at International Conference on Immune Tolerance in Amsterdam

September 29, 2014

MODI’IN, Israel--(BUSINESS WIRE)--Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced today Lawrence Cohen, CEO...

September 29, 2014

CLEVELAND--(BUSINESS WIRE)--The Ohio Clinical Trials Collaborative (OCTC) will join 100 companies and organizations presenting at the 14th annual Biotech in Europe Forum for Global Partnering and Investment Sept. 30-Oct. 1 in Basel, Switzerland....

September 29, 2014

ATLANTA--(BUSINESS WIRE)--At the 60th Annual ASIS International Seminar and Exhibit, the Bruker Detection division introduces RoadRunner™, an innovative, hand-held explosives and narcotics trace detector with outstanding sensitivity, selectivity...

September 29, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014...

September 29, 2014

BOTHELL, Wash. & OSAKA, Japan--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as...

September 29, 2014

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia® to Baxter in its strategic agreement...

September 29, 2014

LOS ANGELES--(BUSINESS WIRE)--PBYI announced positive initial data from the ongoing, open label Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with NSCLC with HER2 mutations.

September 29, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals Data Presented at ESMO 2014 Congress Show Ablative, Bystander Effects of PV-10

September 29, 2014

GÖTEBORG, Sweden & RADNOR, Pa.--(BUSINESS WIRE)--Cortendo AB (OAX:CORT) Cortendo AB [ticker: CORT on NOTC-A], a biopharmaceutical company developing and commercializing products at the intersection of orphan diseases and endocrinology...

September 29, 2014

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

September 29, 2014

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in Patients with Advanced Bladder Cancer at ESMO 2014

September 29, 2014

DARMSTADT, Germany--(BUSINESS WIRE)--Product innovations and geographical expansion drive sustained Merck Consumer Health business growth

September 29, 2014

HARROGATE, England--(BUSINESS WIRE)--Mayor and Mayoress Open Smithers Viscient EU Research Laboratory in Harrogate

September 29, 2014

PRINCETON, N.J.--(BUSINESS WIRE)--Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results.

September 29, 2014

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the coBRIM Phase III study. The results showed that people with previously untreated BRAF V600...

September 29, 2014

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, evaluating...

September 29, 2014

GÖTEBORG, Sweden and RADNOR, Pa.--(BUSINESS WIRE)--Regulatory News: Cortendo AB(OSE:CORT): Cortendo AB [ticker: CORT on NOTC-A], a biopharmaceutical company developing and commercializing products at the intersection of orphan diseases and...

September 29, 2014

BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc Receives FDA’s First Ever Drug Shortage Assistance Award

September 29, 2014

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (NYSE-Euronext: TNG)(Paris:TNG) today announced the presentation1 of more mature data from the Phase 2b part of the TIME trial with TG4010 MUC1 targeted immunotherapy at the...

September 28, 2014

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary...

September 28, 2014

LONDON--(BUSINESS WIRE)--Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation...

September 28, 2014

EAGAN, Minn.--(BUSINESS WIRE)--Biothera will present today results on its investigational immunotherapy Imprime PGG® in combination with standard of care frontline chemotherapy and bevacizumab in patients with stage IV nonsquamous non-small cell...

September 28, 2014

BEERSE, Belgium--(BUSINESS WIRE)--ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer

September 28, 2014

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer at ESMO 2014

September 28, 2014

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta® (pertuzumab) to...

September 28, 2014

BOULDER, Colo.--(BUSINESS WIRE)--Clovis reports updated data from Phase 2 studies of rucaparib at ESMO 2014

September 27, 2014

INGELHEIM, Germany--(BUSINESS WIRE)--For Ex-US and Ex-UK Media Only Phase III data from Boehringer Ingelheim’s LUX-Lung 8 trial, the first study to directly compare the efficacy of two different targeted agents in patients with advanced squamous...

September 27, 2014

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation at the ESMO 2014 Congress (26-30 September in Madrid) of the preliminary results of the phase II proof-of-concept clinical trial with...

September 26, 2014

DALLAS--(BUSINESS WIRE)--Vivione Biosciences Inc. today announced the termination of Ted Moskal as President of Vivione and its operating subsidiary, Vivione Biosciences, LLC.

September 26, 2014

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its management will host a conference call and webcast on Monday, September 29, 2014, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET)...

September 26, 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Reports FDA approval of ILUVIEN for Diabetic Macular Edema - pSivida earns $25 million milestone payment